Cary-based Altavant Sciences acquires drug firm in first deal as part of new conglomerate

Altavant Sciences, an emerging biophmarceutical firm that recently became part of a new drug conglomerate through a $3 billion deal, has in turn acquired a Pennsylvania drug development company.